Publications

Richmond Pharmacology is committed to publishing data from clinical trials, however, we will only do so in agreement with our clients or where we own the intellectual property. This page provides access to a selection of publications grouped by the area of research.

Cardiac Safety

QT prolongation in healthy Japanese subjects receiving moxifloxacin in Thorough QT studies. Taubel et al. The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), 1-3 December 2011, Tokyo, Japan. Program


Sex differences on the effect of moxifloxacin – A meta-analysis of five Thorough QT Studies. Taubel et al. The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), 1-3 December 2011, Tokyo, Japan.


Alternative methods for the confirmation of assay sensitivity in Thorough QT studies. Taubel et al. The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), 1-3 December 2011, Tokyo, Japan. Program


Retrospective analysis of ECG data derived from a four-way cross over study involving a broad spectrum anti-infective agent nitazoxanide. Taubel et al. Pharmacology 2013, London, UK, 17-19 December 2013


Moxifloxacin effect on QTc interval in the fed and fasted states in Thorough QT studies. Jorg Taubel MD FFPM. DIA/FDA Cardiovascular Safety in Drug Development: State-of-the-art Assessments, Washington 18th April 2012


The Impact of Insulin Levels on QTc Interval in Thorough QT Studies Conducted in Healthy Subjects. Taubel et al. ACCP Annual Meeting, San Diego 23-25 September 2012


Retrospective Validation using PK-PD modelling of ECG data derived from a Single Ascending Dose study in accordance with the principles of the ICH E14 guideline utilising the effects of a Meal to establish assay sensitivity. 2013 Annual Meeting


Comparison of digital 12-lead ECG and digital 12-lead holter ECG recordings in health male subjects. 112th ASCPT Annual Meeting, March 2-5, 2011, Dallas, TX. Poster Number: PI-08, scheduled on 3/3/2011 from 8:00 AM.


Late Changes After a Euglycaemic Insulin Clamp Can Lead to Significant Increases in QTcF In Healthy Subjects. Taubel et al. 2012 ACCP Annual Meeting, San Diego 23-25 September 2012


Confirmation of the Cardiac Safety of Rupatadine in a Single Ascending Dose and Multiple Ascending Dose Study in Japanese Healthy Subjects Using Intensive ECG Assessments. Jorg Taubel · Georg Ferber · Inaki Izuierdo. 2015 Annual Meeting, San


Investigating the effect of intravenous APD421 (Amilsulpride) and the ethnic differences between Japanese and Caucasians on cardiac conduction. Jorg Taubel · Georg Ferber · Gabriel Fox · Sara Fernandes · Ulrike Lorch · A John Camm. Tokyo, The


The Power Of Phase I Studies To Detect Clinically Relevant Qtc Prolongation – Results From A Resampling Simulation Study. Ferber et al. The 35th Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), 4-6


Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QTc interval in healthy volunteers. Taubel et al. Br J Clin Pharmacol 2012;74(2): 296-303


Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers. Taubel et al. Br J Clin Pharmacol 2012;75(2): 392-403


Lamotrigine does not prolong QTc in TQT studies in healthy subjects. Dixon R et al. Br J Clin Pharmacol 2008;66(3):396-404


Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Taubel J et al. Br J Clin Pharmacol 2014;77 (1), 170-179


Mason-Likar electrode configuration can confound the recognition of electrode cable interchange. Velislav N et al. J Electrocard, 2010.12.164


Investigating the Ethnic Differences between the Effect of Moxifloxacin on Cardiac Conduction in Japanese and Caucasians. Dr Jorg Taubel MD FFPM. 5th DIA Cardiac Safety Workshop in Japan, 24 October 2014, Tokyo, Japan 


Comparison of Six Commonly Used QT Correction Models and Their Parameter Estimation Methods. Wang et al. Journal of Biopharmaceutical Statistics 2012; 22(6):1148-1161


Shortening of the QT Interval After Food Can Be Used to Demonstrate Assay Sensitivity in Thorough QT Studies. Taubel et al. J Clin Pharmacol, 2012;52:1558-1565


Levofloxacin can be used as a positive control in QT/QTc studies in healthy subjects (paper). Taubel J et al. Br J Clin Pharmacol 2010;69(4):391-400


Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers. Naseem et al. J Clin Pharmacol, 2012;52:1441-1447


Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects. Sugiyama et al. Br J Clin Pharmacol 2011;73(3): 455-459


Analyzing the Relationship of QT Interval and Exposure to Nitazoxanide, a Prospective Candidate for Influenza Antiviral Therapy – A Formal TQT Study. Taubel et al.  J Clin Pharmacol, 2014. Submitted for publication 24 February 2014;


Concentration-Effect Modeling Based on Change From Baseline to Assess the Prolonging Effect of Drugs on QTc Together With an Estimate of the Circadian Time Course. Ferber et al.  J Clin Pharmacol, 2014. Submitted for publication 3 April 2014;


Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval – A Retrospective Validation by Pharmacokinetic- Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay


Assay Sensitivity in QT Assessment. Taubel J et al. Journal for Clinical Studies 2015, 7(6): 60-62


Clinical Pharmacology and Adaptive Early Phase Studies

Clinical Trials: A Practical Guide to Design, Analysis, and Reporting Crossover Trials Bioequivalence Trials Source and Control of Bias


The pharmacokinetic interaction between isoniazid/pyrazinamide and TMC207, an investigational antimycobacterial agent. van Heeswijk R et al.


PET500 A Newly Formulated Tetracaine Product is Effective in Reducing Penile Sensitivity. Taube et al. Thirty-Ninth Annual Meeting American College of Clinical Pharmacology September 12-14, 2010 Baltimore, Maryland. J Clin Pharmacol, September


Analysis of safety, pharmacokinetic and pharmacodynamic data derived from a single ascending dose Phase 1 study involving a promising non-cytotoxic anti-cancer agent Sulforadex®. Taubel et al. Pharmacology 2013, London, UK, 17-19 December 2013


No clinically relevant effect of TMC125 on the pharmacokinetics of oral contraceptives. Schöller-Gyüre M et al.


A phase I, randomised single center, open-label parallel group trial to compare the pharmacokinetics of NOMAC between healthy female adolescents (aged 14-17 years) and healthy female adults (aged 18-50 years) after single dose administration of


The influence of a low fat diet and hospitalisation on liver function tests in healthy Japanese and Caucasian male volunteers resident in a Phase I unit for up to 34 days. 2013 Annual Meeting of the American College of Clinical Pharmacology


How adaptive study design can enrich an early phase multiple ascending dose study. Lorch et al.  2014 Annual Meeting of the American College of Clinical Pharmacology (ACCP),Atlanta, GA , 14-16 September 2014


Ascending single-dose study with ACT-280778, a non-dihydropyridine, dual L- and T-type calcium channel blocker: safety, tolerability, pharmacokinetics, and effect of food in healthy male subjects. Mueller MS et al. Presented at the American


Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously. Freston J et al. The American Journal of Gastroenterology Vol. 96, No. 7, 2001


Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-inhuman study Zhenhua Xu et al. Br J Clin Pharmacol 2011 72(2) / 270-281


Cizolirtine Citrate (E-4018) in the Treatment of Chronic Neuropathic Pain. Shembalkar P et al. Curr Med Res Opin 17(4):262-266, 2001


Rule Britannia – the advantages of conducting first-time-in-human (FTIH) studies in the UK compared to other European markets. Taubel J, Berelowitz K, Lorch U. International Clinical Trials P16+ February 2011


The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings. Lorch et al. Eur J Clin Pharmacol (2012) 68:543-551


Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies. Jorup et al. BMC Pulmonary Medicine 2014, 14:52


Early phase clinical trials in the United Kingdom. Jorg Taubel, Richmond Pharmacology Ltd and David Rogers, Medicines Evaluation Unit Ltd, Wythenshawe Hospital.


Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. Lorch et al. BMC Medical Research Methodology 2014, 14:84 http://www.biomedcentral.com/1471-2288/14/84  


Early phase clinical trials in the United Kingdom. Jorg Taubel, Richmond Pharmacology Ltd and David Rogers, Medicines Evaluation Unit Ltd, Wythenshawe Hospital. CCRA Yearbook 2014, pp 9-10


Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. Lorch et al. BMC Medical Research Methodology 2014, 14:84 http://www.biomedcentral.com/1471-2288/14/84


Japanese Studies

The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist,in healthy Japanese volunteers. Lorch et al. ERS 2012, September 1-5, Vienna, Austria


Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch. Lefèvre et al. J Clin Pharmacol April 2009 49: 430-443


Gastric Acid Suppression Effect of TAK-438, A Potassium-Competitive Acid  Blocker Following Ascending Single Doses in Healthy Subjects. Sakurai et al. 20th United European Gastroenterology Week, Amsterdam, The Netherlands, 20-24 Oct 2012. GUT


Pharmacokinetics and tolerability of sublingual fentanyl in healthy Japanese and Caucasian volunteers: Phase I, open-label, single-dose study. Lorch U et al.


Gastric Acid Suppression Effect of TAK-438, A Potassium-Competitive Acid  Blocker Following Ascending Multiple Doses in Healthy Subjects. Jenkins et al. 20th United European Gastroenterology Week, Amsterdam, The Netherlands, 20-24 Oct 2012. GUT


Pharmacokinetics, Safety and Tolerability of Rupatadine in Healthy Japanese Volunteers. Jorg Taubel · Eva Santamaria. 2015 Annual Meeting of the American College of Clinical Pharmacology, San Francisco, CA; 09/2015


Early Phase Japanese Bridging Studies; Their Global Significance and What to Look for when Selecting a Suitable Contract Research Organisation to Conduct these Studies. Berelowitz K et al. International Pharmaceutical Industry; Volume 3, Issue


Lomitapide single-and multiple-dose exposure in Japanese and Caucasian subjects: results of a Phase 1 pharmacokinetic and pharmacodynamic study. Taubel et al. The 46th Annual Scientific Meeting of the Japan Atherosclerosis Society, Tokyo, Japan,


Patient Studies

An open-label, parallel-group, repeat-dose study to investigate the effects of end-stage renal disease and haemodialysis on the pharmacokinetics of ropinirole. Tompson et al. 13th International Congress of Parkinson’s Disease and Movement


Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. Davies B et al. Br J Clin Pharmacol 2010;70(6):834-843. Single centre drug interaction study in 20 patient volunteers on regular warfarin. The study


Benefits of a Single Versus Multicenter Approach in Early-Phase Patient Studies; A Case Study of Multiple Sclerosis Patients. Berelowitz et al. The Monitor Page 21-25. October 2011


Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study. Wolf et al. PLOS ONE Journal. March 2013 | Volume 8 | Issue 3 | e58438


Corporate Information

Richmond Pharmacology Limited Financial Statements for the Year Ended 31 December 2013. Company Registration Number 04269261 Financial Statements for prior years are available on request – Click here for contact and enquiries


MHRA Phase I Accreditation Certificate (March 2013)


MHRA Phase I Accreditation Certificate (March 2015)


MHRA Phase I Accreditation Certificate (April 2017)





Testimonials

“I am very pleased with the Project Management of both studies undertaken on behalf of (blank) and any future studies we have to outsource will automatically be contracted to you.”

- Anonymous

“Many thanks for your time today, most impressed with the quality of the follow up to our enquiry.”

- Anonymous

“Please know that it has been an absolute pleasure collaborating with you and that I am most appreciative of the key contributions RPL has made to this project thus far. I hope I have the opportunity to work with RPL again in the very near future.”

- Anonymous

Latest news

DIA, Chicago 2017

23rd Jun 2017

Richmond Pharmacology is a frequent contributor and recognised thought leader for various scientific meetings

Read more ›

Richmond Pharmacology’s New London Bridge unit offers unrivalled access to patient recruitment

28th Apr 2017

Richmond Pharmacology has been settling into life in its New London Bridge Research Unit.

Read more ›

New CRO unit facility welcomes first overnight patients

31st Mar 2017

Richmond Pharmacology has been busy settling in their first patients at the new London Bridge site.

Read more ›

American Society for Clinical Pharmacology and Therapeutics (ASCPT)

Mar 15th 2017 | Washington, D.C

Richmond Pharmacology is attending the American Society for Clinical Pharmacology and Therapeutics (ASCPT) event in Washington DC over the next few days.

View all events ›